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Summary
Background For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been 
doxorubicin. This study compared gemcitabine and docetaxel versus doxorubicin as first-line treatment for advanced 
or metastatic soft-tissue sarcoma.
Methods The GeDDiS trial was a randomised controlled phase 3 trial done in 24 UK hospitals and one Swiss 
Group for Clinical Cancer Research (SAKK) hospital. Eligible patients had histologically confirmed locally 
advanced or metastatic soft-tissue sarcoma of Trojani grade 2 or 3, disease progression before enrolment, and no 
previous chemotherapy for sarcoma or previous doxorubicin for any cancer. Patients were randomly assigned 1:1 
to receive six cycles of intravenous doxorubicin 75 mg/m² on day 1 every 3 weeks, or intravenous gemcitabine 
675 mg/m² on days 1 and 8 and intravenous docetaxel 75 mg/m² on day 8 every 3 weeks. Treatment was assigned 
using a minimisation algorithm incorporating a random element. Randomisation was stratified by age (≤18 years 
vs >18 years) and histological subtype. The primary endpoint was the proportion of patients alive and progression 
free at 24 weeks in the intention-to-treat population. Adherence to treatment and toxicity were analysed in the 
safety population, consisting of all patients who received at least one dose of their randomised treatment. The 
trial was registered with the European Clinical Trials (EudraCT) database (no 2009–014907–29) and with the 
International Standard Randomised Controlled Trial registry (ISRCTN07742377), and is now closed to patient 
entry.
Findings Between Dec 3, 2010, and Jan 20, 2014, 257 patients were enrolled and randomly assigned to the two treatment 
groups (129 to doxorubicin and 128 to gemcitabine and docetaxel). Median follow-up was 22 months (IQR 15·7–29·3). 
The proportion of patients alive and progression free at 24 weeks did not differ between those who received doxorubicin 
versus those who received gemcitabine and docetaxel (46·3% [95% CI 37·5–54·6] vs 46·4% [37·5–54·8]); median 
progression-free survival (23·3 weeks [95% CI 19·6–30·4] vs 23·7 weeks [18·1–20·0]; hazard ratio [HR] for progression-
free survival 1·28, 95% CI 0·99–1·65, p=0·06). The most common grade 3 and 4 adverse events were neutropenia 
(32 [25%] of 128 patients who received doxorubicin and 25 [20%] of 126 patients who received gemcitabine and 
docetaxel), febrile neutropenia (26 [20%] and 15 [12%]), fatigue (eight [6%] and 17 [14%]), oral mucositis 
(18 [14%] and two [2%]), and pain (ten [8%] and 13 [10%]). The three most common serious adverse events, representing 
111 (39%) of all 285 serious adverse events recorded, were febrile neutropenia (27 [17%] of 155 serious adverse events 
in patients who received doxorubicin and 15 [12%] of 130 serious adverse events in patients who received gemcitabine 
and docetaxel, fever (18 [12%] and 19 [15%]), and neutropenia (22 [14%] and ten [8%]). 154 (60%) of 257 patients died in 
the intention-to-treat population: 74 (57%) of 129 patients in the doxorubicin group and 80 (63%) of 128 in the 
gemcitabine and docetaxel group. No deaths were related to the treatment, but two deaths were due to a combination 
of disease progression and treatment.
Interpretation Doxorubicin should remain the standard first-line treatment for most patients with advanced soft-
tissue sarcoma. These results provide evidence for clinicians to consider with their patients when selecting first-line 
treatment for locally advanced or metastatic soft-tissue sarcoma.
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Introduction
Soft-tissue sarcoma comprises a number of rare 
malignancies, with 3298 patients newly diagnosed with 
the disease in the UK in 2010.1 Surgery with radiotherapy 
is the most common treatment for localised disease, with 
associated 5-year overall survival of 55% in 2006–10.1 
Survival outcomes for locally advanced or metastatic soft-
tissue sarcoma are poor, with a median overall survival of 
12·8–14·3 months after diagnosis.2,3 Doxorubicin has 
been used as first-line treatment for locally advanced or 
metastatic soft-tissue sarcoma for more than 40 years. A 
randomised controlled phase 3 trial2 comparing 
combination doxorubicin and ifosfamide versus 
doxorubicin alone showed a significant increase in 
progression-free survival in the combination treatment 
group, but with no increase in overall survival. Toxicity 
was predictably higher in the combination group, and the 
authors concluded their results “do not support the use of 
intensified doxorubicin and ifosfamide for palliation of 
advanced soft-tissue sarcoma unless the specific goal is 
tumour shrinkage”. Subsequently, two first-line phase 3 
trials4,5 have combined doxorubicin with novel agents 
(doxorubicin and palifosfamide compared with doxo-
rubicin and placebo,4 and doxorubicin and evofosfamide 
compared with doxorubicin alone5), and neither study 
was able to show improved progression-free survival or 
overall survival for the combination treatments. Thus, no 
regimen has proved to be unequivocally superior to 
doxorubicin as first-line treatment for locally advanced or 
metastatic soft-tissue sarcoma.
Gemcitabine and docetaxel was first reported as a 
treatment for locally advanced or metastatic soft-tissue 
sarcoma in 2002. Hensley and colleagues6 did a phase 2 
study in patients with leiomyosarcoma and reported that 
53% of patients achieved an objective response. This study 
also compared plasma levels of gemcitabine achieved with 
a 90-min infusion versus a 30-min infusion, and showed 
that the 90-min infusion was associated with a longer 
duration of plasma gemcitabine concentrations above 
10 µmol/L, which is the threshold for saturation of 
intracellular accumulation of the active form of the drug, 
gemcitabine triphosphate. A further retrospective review of 
gemcitabine and docetaxel in patients with locally advanced 
or metastatic disease included an in-vitro study to 
investigate the dosing sequence of gemcitabine and 
docetaxel, finding that gemcitabine followed by docetaxel 
was synergistic, whereas docetaxel followed by gemcitabine 
was antagonistic.7 Hence, the currently used schedule of 
gemcitabine and docetaxel in locally advanced or metastatic 
soft-tissue sarcoma was established. Subsequently, several 
Research in context
Evidence before this study
In 2008, when this study was designed, we searched PubMed 
for randomised controlled trials that compared single-agent 
doxorubicin with other schedules used in first-line treatment 
of advanced soft-tissue sarcoma, published in English, with no 
start date restriction, until Dec 15, 2008. We used the 
following search terms: “soft tissue”, “sarcoma”, 
“chemotherapy”, “doxorubicin”, “gemcitabine”, “docetaxel”, 
“randomised”, and “trial”. We identified six published 
randomised controlled trials, none of which showed a survival 
advantage for any schedule over single-agent doxorubicin. We 
identified a further randomised controlled study comparing 
single-agent doxorubicin versus doxorubicin and ifosfamide 
chemotherapy, which was recruiting at that time, and which 
has since been published in 2014, showing an advantage for 
the combination for progression-free survival but not overall 
survival. We also searched for randomised controlled trials 
comparing doxorubicin versus gemcitabine and docetaxel. 
Although we identified three phase 2 studies (one of which 
was a randomised phase 2 study comparing gemcitabine 
versus gemcitabine and docetaxel), we were unable to find any 
phase 3 trials comparing this combination with doxorubicin.
Added value of this study
To our knowledge, this is the first randomised controlled trial 
that compares two commonly used treatments—doxorubicin 
versus gemcitabine and docetaxel—as first-line treatment in 
advanced soft-tissue sarcoma. We have shown that gemcitabine 
and docetaxel was not superior to doxorubicin for either 
progression-free survival or overall survival. Furthermore, 
planned subgroup analyses have not identified any subgroup for 
which gemcitabine and docetaxel was superior, and in particular 
we did not observe superiority for either leiomyosarcoma or 
uterine leiomyosarcoma, for which gemcitabine and docetaxel 
has previously been believed to be particularly active. We found 
worse treatment adherence with gemcitabine and docetaxel 
compared with doxorubicin, with more dose delays, lower dose 
intensity, and more patients stopping treatment early due to 
toxicity, and lower quality-of-life scores.
Implications of all the available evidence
These results provide evidence for clinicians to consider with 
patients when selecting first-line treatment for advanced 
soft-tissue sarcoma. Although the observed similar 
progression-free survival and overall survival of gemcitabine 
and docetaxel and doxorubicin might support a conclusion that 
either schedule can be used according to patient or clinician 
preference, our results indicate the need for caution with such 
an approach given the greater difficulty in delivery and toxicity 
of gemcitabine and docetaxel, and indeed the higher cost of 
this combination regimen. The data support the conclusion 
that doxorubicin should remain standard of care as first-line 
treatment for most patients with advanced soft-tissue 
sarcoma, and that there is no subgroup of patients for whom 
gemcitabine and docetaxel should be routinely recommended.
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retrospective studies and phase 2 studies, in both 
leiomyosarcoma8–11 and unselected soft-tissue sarcoma,7,12,13 
have all showed activity of the combination. The observed 
responsiveness of leiomyosarcoma in particular has led to 
some clinicians adopting gemcitabine and docetaxel as a 
first-line treatment option for locally advanced or metastatic 
leiomyosarcoma, in the absence of evidence from phase 3 
trials. With increasing use of the combination in both 
leiomyosarcoma and locally advanced or metastatic soft-
tissue sarcoma, robust evidence is needed to establish the 
roles of gemcitabine and docetaxel and doxorubicin as first-
line treatments for this disease.
The GeDDiS trial aimed to compare the efficacy of 
gemcitabine and docetaxel versus doxorubicin in the first-
line setting for locally advanced or metastatic soft-tissue 
sarcoma. We also compared toxicity and quality of life for 
the two regimens to aid clinical decision-making in 
treatment selection for individual patients. A pharmaco-
genomics study was also done to investigate the influence 
of single-nucleotide polymorphisms (SNPs) on treatment 
efficacy and toxicity.
Methods
Study design and participants
GeDDiS was a multicentre, randomised, phase 3 trial, 
which recruited patients from 24 UK hospitals, and one 
Swiss Group for Clinical Cancer Research (SAKK) hospital 
in Switzerland (appendix p 1). Eligible patients were at 
least 13 years old (with the aim to encourage participation 
of the teenage and young adult population), with 
histological confirmation of high-grade advanced soft-
tissue sarcoma (defined as Trojani grade 2 or 3), 
measurable disease according to the Response Evaluation 
Criteria In Solid Tumors version 1.1 (RECIST 1.1),14 
evidence of disease progression in the previous 6 months 
(defined as radiological progression when comparing 
current imaging to a previous disease assessment done 
within the previous 6 months; clinical progression was 
accepted in patients for whom there were concerns 
regarding treatment delays incurred by awaiting 
radiological disease progression, on discussion with the 
chief investigator), no previous chemotherapy for 
sarcoma, no previous doxorubicin for any previously 
treated cancer, WHO performance status 0–2, and a life 
expectancy of at least 3 months. Patients were required to 
have adequate organ function (absolute neutrophil count 
≥1·0 × 10⁹ per L; platelet count ≥100 × 10⁹ per L; bilirubin 
≤1·5 × upper limit of normal [ULN]; aspartate trans-
aminase, alanine transaminase, or both ≤3·0 × ULN; 
alkaline phosphatase ≤3·0 × ULN [patients were eligible 
with a higher alkaline phosphatase concentration if this 
was shown to be due to bone isoenzyme]; measured or 
calculated creatinine clearance ≥30 mL/min; and cardiac 
ejection fraction within local normal limits). Tumour 
tissue was required to be available for central review.
Patients were excluded from the trial if they had alveolar 
soft part sarcoma, gastrointestinal stromal tumour, Ewing’s 
sarcoma, alveolar or embryonal rhabdomyosarcoma, 
desmo plastic small round cell tumour, extraskeletal myxoid 
chondrosarcoma, dermatofibrosarcoma protuberans, 
malignant mixed mesodermal tumour or carcinosarcoma 
of the uterus, smooth muscle tumours of uncertain 
malignant potential of uterus, known active or uncontrolled 
brain metastases, active uncontrolled infection, or grade 3 
or 4 peripheral neuropathy. Pregnant or lactating women 
were excluded, as were patients with a history of malignancy 
other than sarcoma (exceptions included basal or squamous 
cell carcinoma of the skin and carcinoma in situ of the 
cervix, breast, or prostate) within 3 years before enrolment.
Samples of formalin-fixed, paraffin-embedded tumour 
tissue and haematoxylin and eosin-stained slides 
were submitted for central review for confirmation of 
sarcoma diagnosis and histological subtype, although 
patients were enrolled on the basis of the local 
pathology report. All samples were reviewed by a single 
histopathologist (RT).
The trial was approved by the National Research Ethics 
Service Committee: London, Bloomsbury (10/H0713/54), 
the Medicines and Healthcare Products Regulatory Agency 
(Clinical Trials Authorisation number 20363/0285/001–
0001), and by the Research and Development department 
of each participating NHS Trust. 
The trial was done according to the principles of the 
International Conference on Harmonisation on Good 
Clinical Practice. All patients gave written informed 
consent before enrolment and undergoing any trial-
specific procedures. The trial protocol is available online.
Randomisation and masking
Patients were randomly allocated in a 1:1 ratio to receive 
either gemcitabine and docetaxel or doxorubicin. 
Treatment was assigned centrally by computer at the 
Cancer Research UK and University College London 
Cancer Trials Centre (UCL CTC; London, UK) using a 
minimisation algorithm incorporating a random 
element. Patients were stratified by age (≤18 years vs 
>18 years) and histological subtype (uterine 
leiomyosarcoma vs synovial sarcoma vs pleomorphic 
sarcoma vs other eligible sarcomas). We chose these 
specific histological strata on the basis of available 
evidence at the time of trial design suggesting potential 
differential disease response to chemotherapy in the 
different strata (uterine leiomyosarcoma and 
pleomorphic sarcomas might be more sensitive to 
gemcitabine and docetaxel, and synovial sarcomas are 
recognised as being generally more sensitive to chemo-
therapy than other subtypes). Treatment allocation was 
communicated electronically to the site randomising the 
patient. Treatment allocation was not masked.
Procedures
Patients received either intravenous doxorubicin 75 mg/m² 
on day 1 every 3 weeks, or intravenous gemcitabine 
675 mg/m² on day 1 and intravenous gemcitabine 
For the protocol see 
http://www.ctc.ucl.ac.uk/
TrialDetails.aspx?Trial=72& 
TherA=9
See Online for appendix
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675 mg/m² followed by intravenous docetaxel 75 mg/m² on 
day 8 every 3 weeks. Gemcitabine was administered over 
90 min and docetaxel was administered over 60 min. Dose 
capping according to sites’ local policy and dose banding to 
within plus or minus 5% of the calculated dose were 
permitted. Pre-treatment and post-treatment anti-emetics 
were given for all trial treatments, as per local anti-emetics 
policy. In both groups, patients completed up to six cycles 
of treatment in the absence of disease progression, 
intolerable side-effects, or withdrawal of consent.
Laboratory monitoring (blood count and biochemistry) 
was done within 72 h of day 1 of each cycle, with 
additional monitoring on day 8 (blood count only) for 
gemcitabine and docetaxel treatment. To proceed with 
treatment on day 1 of each cycle (both groups) the 
following were required: absolute neutrophil count of at 
least 1·0 × 10⁹ per L, platelet count of at least 100 × 10⁹ per 
L, bilirubin of up to 1·5 × ULN, and aspartate 
transaminase, alanine trans aminase, or both of up to 
3·0 × ULN. For administration of treatment on day 8 (in 
the gemcitabine and docetaxel group) the following were 
required: absolute neutrophil count of at least 
1·0 × 10⁹ per L and platelets of at least 75 × 10⁹ per L. Dose 
modifications for adverse events were made according to 
prespecified criteria: dose reductions of 20% (first 
occurrence) ND then 33% (second occurrence) were 
permitted for doxorubicin (in the case of grade 3 or worse 
febrile neutropenia) and gemcitabine and docetaxel (for 
grade 3 or worse febrile neutropenia, grade 2 neuropathy, 
or any grade pulmonary toxicity); a third occurrence 
required the patient to be withdrawn from treatment. 
Granulocyte colony-stimulating factor was permitted 
after an episode of febrile neutropenia, at the discretion 
of the treating investigator and according to local policy. 
Dose delays of up to 2 weeks for haematological toxicity 
and up to 3 weeks for non-haematological toxicity were 
allowed; delays longer than this required the patient to be 
withdrawn from treatment. For doxorubicin, patients 
were advised to be withdrawn from treatment if left 
ventricular ejection fraction was less than 45% or reduced 
by 20% from baseline (cardiotoxicity monitoring was 
done according to local institutional policies). For 
gemcitabine and docetaxel, patients were withdrawn for 
the following events: grade 3 pulmonary fibrosis, any 
grade 4 pulmonary toxicity, grade 3 or 4 hypersensitivity 
reactions (docetaxel only), or grade 3 weight gain.
Adverse events were assessed according to the 
National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.03, from 
informed consent until 30 days after last trial treatment 
administration. Serious adverse events were reported 
from informed consent until 30 days after last trial 
treatment administration, or later if the investigator felt 
that an event was related to trial treatment.
Disease status was assessed by CT scan, MRI scan, or 
both at baseline, 12 and 24 weeks after randomisation, 
and then every 12 weeks until disease progression 
(including patients who discontinued treatment for any 
reason other than disease progression). Response was 
assessed by local investigators according to RECIST 1.1. 
Additionally, scans for 15% of recruited patients were 
centrally reviewed at University College Hospital. At least 
one patient from every site had a central scan review (10% 
of patients for sites recruiting ten patients or more). All 
scan images (baseline and subsequent disease 
assessments) available for these patients were reviewed.
Quality of life was assessed at baseline and at 12, 18, 
and 24 weeks after randomisation, using the EORTC 
QLQ-C30, and fatigue-specific FA-13 questionnaires. 
Health economic assessment was also done at the same 
timepoint using the EuroQoL EQ-5D questionnaire, and 
by prospectively collecting information about health-care 
resource use. 
For the pharmacogenomics analyses, DNA was 
extracted from 4 mL whole blood using a QIAamp DNA 
Blood Maxi kit (Qiagen, Manchester, UK), according to 
the manufacturer’s instructions. All samples were diluted 
to 10 ng/μL DNA in AE buffer, before being genotyped by 
Taqman PCR on a 7900HT PCR machine. Individual 
candidate SNPs in genes associated with the 
pharmacology of the three drugs were identified from 
relevant published literature,15–21 and Taqman Assay on 
Demand probes (Applied Biosystems, Paisley, UK) were 
used to genotype the samples.
Outcomes
The primary endpoint was the proportion of patients alive 
and progression free at 24 weeks after the date of 
randomisation. Secondary endpoints were the proportion 
of patients alive and progression free at 12 weeks after the 
date of randomisation, progression-free survival (time 
from randomisation to date of progression or death from 
any cause, whichever occurred first), and overall survival 
(time from randomisation to date of death from any cause), 
the proportion of patients achieving an objective response 
by RECIST 1.1, the proportion of patients achieving an 
objective response by Choi criteria (retrospective analysis), 
assessment of adverse events, quality of life, and health 
economics evaluation. Time to progression, proportion of 
patients achieving an objective response as assessed by 
Choi criteria, the health economics assessment, and the 
planned sensitivity analyses will all be published separately 
at a later date. We also did a pharmacogenomics analysis to 
assess the influence of SNPs on response and toxicity in 
patients assigned to each treatment group. 
Statistical analysis
Under the assumption of a hazard ratio (HR) of 0·63, 
250 patients (and 148 progressions or deaths) were 
required to achieve 80% power with a two-sided α of 5%. 
We assumed a median progression-free survival of 
3·5 months for doxorubicin22 (corresponding with 30% of 
patients achieving 24-week progression-free survival) 
and a median progression-free survival of 5 months 
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(corresponding with 47% of patients achieving 24-week 
progression-free survival) for gemcitabine and docetaxel.6,13
We did the efficacy analysis in the intention-to-treat 
population of all randomised patients. We analysed 
adverse events in the safety population consisting of all 
patients who received at least one dose of their randomly 
assigned treatment. We calculated median follow-up 
using the Kaplan-Meier method, censoring patients at 
date last seen. We plotted Kaplan-Meier curves for 
progression-free survival and overall survival; treatment 
effect HRs (with 95% CIs and p values) were obtained 
from Cox proportional hazards regression models, 
adjusted for randomisation stratification factors. A HR of 
less than 1 favoured the gemcitabine and docetaxel 
group. We tested the proportionality assumption of the 
Cox model with Schoenfeld residuals. 
Although the trial was not powered for subgroup 
analyses, we prospectively planned subgroup analyses 
for histological subtypes. These analyses were exploratory 
by nature, and were performed using tests for interaction.
We presented adverse events as the worst grade per 
patient per event, and comparison between groups was 
done using a test of proportions.
We assessed quality of life at the 12-week post-
randomisation visit. We used ANCOVA and fitted a 
linear regression model adjusting for baseline score, 
stratification factors, and actual time between baseline 
and 12-week assessments (to allow for variation in the 
actual timings of assessments). We prospectively 
planned in our statistical analysis plan to use 99% CIs to 
account for multiple comparisons within the different 
scales of quality of life, which is a robust approach when 
the risk of a type 1 error is inflated by making multiple 
comparisons.
To assess the effect of SNPs on efficacy and toxicity 
within treatment groups, we used Cox proportional 
hazards regressions on overall survival and progression-
free survival and logistic regressions on any grade 3 or 4 
adverse events.
We calculated dose intensity relative to the total 
planned dose using a formula that incorporated delays 
and dose reductions.23
We used STATA version 14.2 for all statistical analyses.
An external independent data monitoring committee 
oversaw the trial and assessed the safety and efficacy 
approximately annually. This study is registered with the 
European Clinical Trials (EudraCT) database (no 2009–
014907–29) and as an International Standard Randomised 
Controlled Trial, number ISRCTN07742377.
Role of the funding source
The trial was sponsored by University College London 
(UCL) and coordinated centrally by Cancer Research UK 
and UCL CTC. Funding from Cancer Research UK 
(C2921/A11561) was used to support the central 
coordination of the trial at UCL CTC. Analysis of the 
pharmacogenomics samples was funded by Sarcoma UK 
(SUK16.2015). The Clinical Trial Unit Kantonsspital 
St Gallen funded the trial in Switzerland. UCL CTC, on 
behalf of the sponsor, was responsible for the study 
design and conduct, including the collection, 
management, statistical analysis and interpretation of 
the data, and the writing of the report, in conjunction 
with the chief investigator (BS). BS, H-MD, SN, SF, and 
SB had access to all the raw data. GJV, DJ, and KK had 
access to the raw data associated with the 
pharmacogenomics analyses. The corresponding author 
had full access to all the data and the final responsibility 
to submit for publication.
Results
Between Dec 3, 2010, and Jan 20, 2014, 257 patients from 
24 UK hospitals and one Swiss hospital (appendix p 1) 
were enrolled and randomly assigned to receive 
doxorubicin (129 patients) or gemcitabine and docetaxel 
(128 patients; figure 1). Our intention-to-treat population 
consisted of these 257 patients. Two randomised patients 
(one in each group) were later found to be ineligible 
(figure 1); however, both are included in the intention-to-
treat analysis and received treatment. Our safety 
population included 254 of the 257 randomised patients, 
2 did not start treatment†
128 allocated to gemcitabine and docetaxel
128 included in intention-to-treat population
126 included in safety population
1 lost to follow-up¶
79 discontinued intervention||
1 did not start treatment†
257 patients enrolled and randomly assigned
497 patients assessed for eligibility
129 allocated to doxorubicin
129 included in intention-to-treat population
128 included in safety population
3 lost to follow-up§
58 discontinued intervention||
240 excluded
91 did not meet inclusion criteria
96 declined to participate
53 other reasons*
126 received allocated intervention (including
1 ineligible patient)‡
128 received allocated intervention (including
1 ineligible patient)‡ 
Figure 1: Trial profile
*Other reasons were: 43 multidisciplinary team decision not to approach patient, five deaths, three referred to or 
treated at other hospital, one patient did not fully understand trial, one trial closed before patient finished 
radiotherapy. †Clinical decision made not to treat (doxorubicin group), withdrawn consent (gemcitabine and 
docetaxel group), disease progression (gemcitabine and docetaxel group). ‡Histology review reclassified as 
ineligible histological subtypes (one gastrointestinal tumour in the doxorubicin group and one extra-skeletal 
myxoid chondrosarcoma in the gemcitabine and docetaxel group). §Two moved away, one being treated locally. 
¶One moved away. ||See appendix p 6 for a breakdown of reasons for treatment discontinuation.
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because one patient who was assigned to doxorubicin 
and two patients who were assigned to gemcitabine and 
docetaxel did not receive at least one dose of their 
allocated treatment (figure 1).
Patient characteristics were similar in the two treatment 
groups at baseline (table 1). Because there was only one 
patient aged 18 years or younger, we excluded this 
stratification factor from all analyses. The analysis is 
based on the dataset in its version of Sept 8, 2015; at this 
point, the estimated median follow-up for all patients 
was 22 months (IQR 15·7–29·3).
Of the 257 randomised patients, 244 (95%) had central 
histopathology review done. 51 (21%) of 244 reports 
differed between the local histology report and the central 
review report, with 36 (14%) major discrepancies 
resulting in reclassification of histology, and 15 (6%) 
minor discrepancies (eg, high-grade spindle cell sarcoma 
being reclassified as pleomorphic sarcoma). A full list of 
major and minor discrepancies is in the appendix 
(pp 3–4). Of the 13 (5%) of 257 patients whose histology 
was not reviewed, six samples were never received, 
one patient had no tissue available, and for six patients 
there was no tumour tissue in the submitted blocks.
More patients in the doxorubicin group (71 [56%] of 
128 patients) received the full six cycles of chemotherapy 
than those in the gemcitabine and docetaxel group 
(49 [39%] of 126 patients). In the gemcitabine and 
docetaxel group, some patients received day 1 gemcitabine 
but not day 8 gemcitabine and docetaxel (gemcitabine: 
cycle 1, eight [6%] of 126 patients; cycle 2, seven [6%] of 
110 patients; cycle 3, five [6%] of 89 patients; cycle 4, 
six [8%] of 75 patients; cycle 5, eight [14%] of 59 patients; 
and cycle 6, three [6%] of 52 patients; appendix p 5). Mean 
dose intensity23 (incorporating dose delays and reductions) 
was 93·7% (SD 0·09) in the doxorubicin group and 
83·4% (SD 0·20) in the gemcitabine and docetaxel group. 
More patients in the gemcitabine and docetaxel group 
experienced dose delays (71 [56%] of 126 patients) than in 
the doxorubicin group (59 [46%] of 128 patients). The 
main reasons for dose delays in both groups were febrile 
neutropenia (seven [12%] of 59 reasons in the doxorubicin 
group vs six [4%] of 155 reasons in the gemcitabine and 
docetaxel group), other haematological toxicities (16 [27%] 
vs 44 [28%]), non-haematological toxicities (five [8%] vs 
seven [5%]), other adverse events (14 [24%] vs 29 [18%]), 
and other practical or social reasons (11 [19%] vs 32 [21%]). 
More patients had dose reductions in the doxorubicin 
group (34 [27%] of 128 patients) than in the gemcitabine 
and docetaxel group (23 [18%] of 126; appendix p 17); the 
main reasons for dose reductions were febrile neutropenia 
(eight [20%] of 41 reasons in the doxorubicin group vs 
one [1%] of 89 reasons in the gemcitabine and docetaxel 
group) and other haematological toxicities (seven [17%] of 
41 vs 26 [29%] of 89). One (1%) of 128 patients in the 
doxorubicin group and 13 (10%) of 126 in the gemcitabine 
and docetaxel group stopped treatment early because of 
toxicity (appendix p 6).
At the time of data analysis, 223 (87%) of 257 patients 
in the intention-to-treat population had experienced 
disease progression; 106 (82%) of 129 patients in the 
doxorubicin group and 117 (91%) of 128 patients in the 
gemcitabine and docetaxel group. An additional ten (8%) 
patients in the doxorubicin group and five (4%) in the 
gemcitabine and docetaxel group died without 
confirmation of progression. 154 (60%) of 257 patients 
died in the intention-to-treat population; 74 (57%) of 
129 patients in the doxorubicin group and 80 (63%) of 
128 patients in the gemcitabine and docetaxel group. No 
deaths were related to the treatment, but two deaths were 
due to a combination of disease progression and 
treatment (see appendix p 10 for the breakdown of causes 
of death by treatment group). As planned, CT or MRI 
scan images were centrally reviewed for 38 (15%) of 
257 patients. No discrepancies were noted between the 
hospitals and the central review for any patients.
Progression-free survival at 24 weeks did not differ 
between the treatment groups (46·3% [95% CI 37·5–54·6] 
in the doxorubicin group vs 46·4% [37·5–54·8] in the 
gemcitabine and docetaxel group; figure 2). Progression-
free survival at 12 weeks was 72·1% (95% CI 63·5–79·0) in 
the doxorubicin group vs 63·8% (54·8–71·5) in the 
gemcitabine and docetaxel group. Median progression-
free survival was 23·3 weeks (95% CI 19·6–30·4) in the 
doxorubicin group and 23·7 weeks (18·1–20·0) in the 
gemcitabine and docetaxel group. The unadjusted HR 
was 1·28 (95% CI 0·99–1·65; p=0·06); after adjusting for 
Doxorubicin 
(n=129)
Gemcitabine 
and docetaxel 
(n=128)
Sex
Male 50 (39%) 51 (40%)
Female 79 (61%) 77 (60%)
Age 56 (49·4–64·0) 55 (45·6–64·0)
≤18 years 1 (1%) 0
Weight (kg) 77·0 (65·7–89·4) 77·7 (63·3–90·9)
WHO performance status
0 55 (43%) 52 (41%)
1 63 (49%) 67 (52%)
2 11 (9%) 9 (7%)
Trojani grade 
2 29 (22%) 34 (27%)
3 85 (66%) 85 (66%)
Not known 15 (12%) 9 (7%)
Histology
Uterine leiomyosarcoma 36 (28%) 35 (27%)
Synovial sarcoma 5 (4%) 6 (5%)
Pleomorphic sarcoma 16 (12%) 16 (13%)
Other eligible sarcomas 72 (56%) 71 (55%)
Non-uterine leiomyosarcoma 24 (19%) 23 (18%)
Data are n (%) or median (IQR). 
Table 1: Baseline characteristics
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histological subtype, the HR was 1·26 (0·97–1·63; p=0·08) 
in favour of doxorubicin. Although the Kaplan-Meier 
curves did not violate the proportional hazards assumption 
(p=0·46 for the adjusted model), they initially overlapped, 
and then separated after 24 weeks.
Overall survival did not significantly differ between the 
two groups. Overall survival at 24 weeks was 86·8% 
(95% CI 79·6–91·6) in the doxorubicin group and 82·6% 
(74·8–88·2) in the gemcitabine and docetaxel group 
(figure 3). Median overall survival was 76·3 weeks 
(95% CI 60·0–91·3) in the doxorubicin group and 
67·3 weeks (53·1–83·1) in the gemcitabine and docetaxel 
group (unadjusted HR 1·14, 95% CI 0·83–1·57; p=0·41).
The proportion of patients achieving an objective 
response by RECIST 1.1 (complete or partial response) 
was similar in the two groups: 25 (19%) of 129 patients in 
the doxorubicin group and 25 (20%) of 128 in the 
gemcitabine and docetaxel group (table 2). 
In our prospectively planned exploratory subgroup 
analysis, no evidence of a differential treatment effect by 
histological subtype was recorded (p=0·24; appendix 
p 11). Further subgroup analyses were done comparing 
leiomyosarcoma versus other sarcomas (p=0·14), and 
uterine leiomyosarcoma versus other sarcomas (p=0·38), 
but again no differential effect was evident between the 
two treatment groups. 
The most common low-grade non-haematological 
adverse event was grade 1 and 2 alopecia, which occurred 
in 110 (86%) of 128 patients in the doxorubicin group and 
95 (75%) of 126 patients in the gemcitabine and docetaxel 
group (table 3). The most common low-grade haemato-
logical adverse event was anaemia (grade 1–2 in 91 [71%] 
patients in the doxorubicin group vs 104 [83%] in the 
gemcitabine and docetaxel group). The most common 
grade 3 and 4 adverse events were neutropenia (32 [25%] 
of 128 patients for doxorubicin vs 25 [20%] of 126 patients 
for gemcitabine and docetaxel), febrile neutropenia 
(26 [20%] vs 15 [12%]), fatigue (eight [6%] vs 17 [14%]), oral 
mucositis (18 [14%] vs two [2%]), and pain (ten [8%] vs 
13 [10%]; table 3). The three most common serious 
adverse events, accounting for 111 (39%) of all 285 serious 
adverse events, were febrile neutropenia (27 [17%] of 
155 serious adverse events in the doxorubicin group vs 
15 [12%] of 130 in the gemcitabine and docetaxel group), 
fever (18 [12%] vs 19 [15%]), and neutropenia (22 [14%] vs 
ten [8%]; appendix pp 7–9).
We compared quality of life between the groups at 
12 weeks postrandomisation. Insufficient questionnaires 
were returned to be able to assess quality of life at 18 weeks 
and 24 weeks (83 [32%] of 257 questionnaires were 
returned at both 18 weeks and 24 weeks, compared with 
132 [51%] of 257 at 12 weeks). Quality-of-life measures did 
not differ between the treatment groups at 12 weeks 
postrandomisation (table 4). However, the mean Global 
Health Status score at 12 weeks was 63·8 (SD 22·5) in the 
doxorubicin group (based on 64 [50%] of 129 patients) and 
59·1 (SD 21·8) in the gemcitabine and docetaxel group 
(based on 63 [49%] of 128 patients). After adjusting for 
baseline score and histological subtype, the mean 
treatment difference was 5·1 (99% CI –4·7 to 15·0; p=0·17; 
figure 4).
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Figure 2: Progression-free survival
HR=hazard ratio.
Figure 3: Overall survival
HR=hazard ratio.
Doxorubicin 
(n=129)
Gemcitabine and 
docetaxel (n=128)
Complete response 2 (2%) 0
Partial response 23 (18%) 25 (20%)
Stable disease 60 (47%) 50 (39%)
Progressive disease 25 (19%) 27 (21%)
Not evaluable 19 (15%) 26 (20%)
Data are n (%).
Table 2: Objective responses
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Doxorubicin (n=128) Gemcitabine and docetaxel (n=126)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Haematological
Anaemia 91 (71%) 10 (8%) 0 104 (83%) 8 (6%) 0
White blood cell decreased 33 (26%) 4 (3%) 6 (5%) 54 (43%) 8 (6%) 1 (1%)
Neutropenia 26 (20%) 15 (12%) 17 (13%) 46 (37%) 15 (12%) 10 (8%)
Platelet count decreased 13 (10%) 1 (1%) 0 31 (25%) 0 0
Febrile neutropenia 0 25 (20%) 1 (1%) 0 13 (10%) 2 (2%)
Non-haematological
Alopecia 110 (86%) 0 0 95 (75%) 0 0
Fatigue 108 (84%) 8 (6%) 0 91 (72%) 17 (14%) 0
Nausea 82 (64%) 5 (4%) 0 69 (55%) 3 (2%) 0
Pain 70 (55%) 10 (8%) 0 66 (52%) 11 (9%) 2 (2%)
Oral mucositis 64 (50%) 18 (14%) 0 59 (47%) 2 (2%) 0
Anorexia 58 (45%) 5 (4%) 0 53 (42%) 2 (2%) 1 (1%)
Constipation 54 (42%) 1 (1%) 0 49 (39%) 2 (2%) 0
Diarrhoea 47 (37%) 3 (2%) 0 42 (33%) 9 (7%) 1 (1%)
Vomiting 46 (36%) 3 (2%) 0 32 (25%) 0 0
Alkaline phosphatase increased 41 (32%) 2 (2%) 0 46 (37%) 2 (2%) 0
Alanine aminotransferase increased 34 (27%) 1 (1%) 0 36 (29%) 1 (1%) 0
Dyspepsia 27 (21%) 1 (1%) 0 18 (14%) 0 0
Hypoalbuminaemia 24 (19%) 4 (3%) 0 40 (32%) 0 0
Fever 24 (19%) 1 (1%) 0 27 (21%) 1 (1%) 0
Dysgeusia 24 (19%) 0 0 25 (20%) 0 0
Cough 23 (18%) 1 (1%) 0 26 (21%) 0 0
Limb oedema 22 (17%) 2 (2%) 0 55 (44%) 0 0
Hyponatraemia 17 (13%) 3 (2%) 0 16 (13%) 7 (6%) 0
Dyspnoea 16 (13%) 3 (2%) 0 24 (19%) 4 (3%) 1 (1%)
Abdominal pain 16 (13%) 4 (3%) 0 14 (11%) 2 (2%) 0
Peripheral sensory neuropathy 14 (11%) 0 0 31 (25%) 0 0
Aspartate aminotransferase increased 14 (11%) 0 0 12 (10%) 1 (1%) 0
Dry mouth 12 (10%) 0 0 5 (4%) 0 0
Urea increased 11 (9%) 0 0 12 (10%) 0 0
Back pain 11 (9%) 1 (1%) 0 11 (9%) 1 (1%) 0
Hyperkalaemia 10 (8%) 1 (1%) 0 18 (14%) 0 0
Insomnia 10 (8%) 0 0 9 (7%) 1 (1%) 0
Urinary tract infection 9 (7%) 0 0 7 (6%) 1 (1%) 0
Dizziness 8 (6%) 2 (2%) 0 4 (3%) 0 0
Hypokalaemia 7 (6%) 2 (2%) 0 7 (6%) 1 (1%) 0
Myalgia 5 (4%) 0 0 12 (10%) 0 0
Pneumonitis 4 (3%) 0 0 7 (6%) 1 (1%) 0
Lower respiratory tract infection 4 (3%) 0 0 4 (3%) 2 (2%) 0
Rash 3 (2%) 0 0 16 (13%) 0 0
Epistaxis 2 (2%) 0 0 13 (10%) 0 0
Herpes zoster virus infection 2 (2%) 0 1 (1%) 0 0 0
Hiccups 2 (2%) 0 0 2 (2%) 1 (1%) 0
Muscle weakness lower limb 2 (2%) 0 0 1 (1%) 1 (1%) 0
Nail infection 2 (2%) 0 0 0 1 (1%) 0
Tumour pain 1 (1%) 1 (1%) 0 3 (2%) 0 0
Hypertension 1 (1%) 1 (1%) 0 1 (1%) 0 0
Hyperglycaemia 1 (1%) 0 0 1 (1%) 1 (1%) 1 (1%)
Allergic reaction 1 (1%) 0 0 3 (2%) 1 (1%) 0
(Table 3 continues on next page)
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Doxorubicin (n=128) Gemcitabine and docetaxel (n=126)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
(Continued from previous page)
Pleural effusion 1 (1%) 0 0 1 (1%) 1 (1%) 0
Chest pain—cardiac 1 (1%) 0 0 0 2 (2%) 0
Urticaria 1 (1%) 0 0 0 1 (1%) 0
Thromboembolic event 0 6 (5%) 2 (2%) 0 2 (2%) 2 (2%)
Lung infection 0 5 (4%) 0 0 3 (2%) 1 (1%)
Syncope 0 3 (2%) 0 0 0 0
Upper respiratory infection 0 2 (2%) 0 0 2 (2%) 0
Vascular access complication 0 2 (2%) 0 0 1 (1%) 0
Rectal haemorrhage 0 1 (1%) 0 3 (2%) 0 0
Infection not otherwise specified 0 1 (1%) 0 0 3 (2%) 0
Skin infection 0 1 (1%) 0 0 2 (2%) 0
Non-cardiac chest pain 0 1 (1%) 0 0 2 (2%) 0
Wound infection 0 1 (1%) 0 0 1 (1%) 0
Acute kidney injury 0 1 (1%) 0 0 0 0
Anal abscess 0 1 (1%) 0 0 0 0
Bone pain 0 1 (1%) 0 0 0 0
Breast pain 0 1 (1%) 0 0 0 0
Bronchopulmonary haemorrhage 0 1 (1%) 0 0 0 0
Colonic ulcer 0 1 (1%) 0 0 0 0
Creatinine decreased 0 1 (1%) 0 0 0 0
GGT increased 0 1 (1%) 0 0 0 0
Heart failure 0 1 (1%) 0 0 0 0
Left ventricular systolic dysfunction 0 1 (1%) 0 0 0 0
Lichen sclerosus 0 1 (1%) 0 0 0 0
Lower gastrointestinal haemorrhage 0 1 (1%) 0 0 0 0
Oral candidiasis 0 1 (1%) 0 0 0 0
Pneumothorax 0 1 (1%) 0 0 0 0
Premature menopause 0 1 (1%) 0 0 0 0
Renal vein thrombosis 0 1 (1%) 0 0 0 0
Skin and subcutaneous tissue disorders: 
Hickman line
0 1 (1%) 0 0 0 0
Tremor 0 1 (1%) 0 0 0 0
Abdominal distension 0 0 0 4 (3%) 1 (1%) 0
Infusion-related reaction 0 0 0 4 (3%) 1 (1%) 0
Skin ulceration 0 0 0 2 (2%) 1 (1%) 0
Cellulitis 0 0 0 1 (1%) 3 (2%) 0
Bronchial Infection 0 0 0 1 (1%) 2 (2%) 0
Night sweats 0 0 0 1 (1%) 1 (1%) 0
Anaphylaxis 0 0 0 0 1 (1%) 0
Ascites 0 0 0 0 1 (1%) 0
Catheter-related infection 0 0 0 0 1 (1%) 0
Diverticulitis 0 0 0 0 1 (1%) 0
Escherichia coli infection at tumour site 0 0 0 0 1 (1%) 0
Electrolyte imbalance 0 0 0 0 1 (1%) 0
Fluid retention 0 0 0 0 1 (1%) 0
Fracture 0 0 0 0 1 (1%) 0
Radiation recall reaction (dermatological) 0 0 0 0 1 (1%) 0
Rectal tenesmus 0 0 0 0 1 (1%) 0
Small intestinal obstruction 0 0 0 0 1 (1%) 0
Stoma site abscess 0 0 0 0 1 (1%) 0
(Table 3 continues on next page)
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For the pharmacogenomics analysis in our translational 
study, total DNA was successfully extracted from 
240 patients: 119 in the doxorubicin group and 121 in the 
gemcitabine and docetaxel group. Frequency and 
distribution of the SNPs investigated were well balanced 
between the treatment groups (appendix p 12). Several 
associations were observed between the SNPs studied, and 
survival and toxicity (appendix pp 12–15). Within the 
doxorubicin group, three of the four SNPs in the SLC22A16 
gene, all in linkage disequilibrium with each other, were 
associated with a worse progression-free survival (appendix 
pp 12, 15), as was the minor allele of the SLC29A1 SNP 
(rs9394992, in both heterozygotes and homozygotes; 
appendix p 14). By contrast, the PRDX4 SNP (rs518329) 
minor allele was associated with improved overall survival 
in the doxorubicin group in both heterozygotes and 
homozygotes (appendix p 13). Analysis of the gemcitabine 
and docetaxel treatment group indicated a possible 
association of the ABCB1 rs1045642 minor allele with 
worse progression-free survival in both heterozygotes and 
homozygotes (appendix p 12); the CDA rs2072671 SNP was 
associated with worse overall survival (appendix p 14), and 
the CMPK1 rs4492666 SNP was associated with improved 
overall survival in both heterozygotes and homozygotes 
(appendix p 14). The SLC22A16 rs723685 minor allele was 
associated with a reduced frequency of grade 3–4 adverse 
events compared with wild type (ten [48%] of 21 patients vs 
69 [71%] of 97 patients) in the doxorubicin treatment group 
but not in the gemcitabine and docetaxel group. No other 
SNPs were associated with grade 3–4 adverse events 
(appendix pp 18–19). 
After completion of treatment within the trial, 58 (23%) 
of 254 patients in the safety population (28 [22%] of 
128 patients receiving doxorubicin and 30 (24%) of 
126 receiving gemcitabine and docetaxel) did not receive 
any additional treatment. The remaining 196 (77%) 
patients received at least one additional treatment: 
chemotherapy for 139 (71%) of 196 patients (62 [62%] of 
100 patients in the doxorubicin group and 77 [80%] of 
96 patients in the gemcitabine and docetaxel group), and 
local therapies for 57 (29%) of 196 patients (38 [38%] 
and 19 [20%]). Local therapies consisted of radiotherapy for 
44 (22%) of 196 patients (28 [28%] and 16 [17%]) and surgery 
for 13 (7%) of 196 patients (ten [10%] and three [3%]). The most 
frequently used second-line chemotherapy regimens were 
Doxorubicin (n=128) Gemcitabine and docetaxel (n=126)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
(Continued from previous page)
Hypercalcaemia 0 0 1 (1%) 0 0 0
Intestinal perforation 0 0 1 (1%) 0 0 0
Sepsis* 0 0 1 (1%) 0 0 0
Myocardial infarction† 0 0 0 0 0 1 (1%)
Sudden death not otherwise specified‡ 0 0 0 0 0 0
Data are n (%).*Sepsis (grade 5) recorded in one patient who received doxorubicin and one patient who received gemcitabine and docetaxel. †Myocardial infarction (grade 5) 
recorded in one patient who received doxorubicin. ‡Sudden death not otherwise specified (grade 5) recorded in one patient who received gemcitabine and docetaxel. GGT=γ 
glutamyltransferase.
Table 3: Adverse events
Treatment effect of gemcitabine 
and docetaxel versus doxorubicin 
(99% CI)*
C30 scales†
Global Health Status (n=120)† –5·1 (–15·0 to 4·7)
Functional scales†
Physical functioning (n=122) –0·5 (–9·8 to 8·8)
Role functioning (n=122) –7·8 (–21·6 to 6·1)
Emotional functioning (n=121) –5·6 (–14·6 to 3·4)
Cognitive functioning (n=121) –3·1 (–12·2 to 6·1)
Social functioning (n=121) 1·5 (–9·8 to 12·9)
Symptom scales‡
Fatigue (n=122) –0·4 (–12·7 to 12·0)
Nausea and vomiting (n=122) –4·6 (–13·5 to 4·2)
Pain (n=122) 5·5 (–7·4 to 18·4)
Dyspnoea (n=122) 1·5 (–11·6 to 14·5)
Insomnia (n=122) 2·2 (–11·6 to 16·0)
Appetite loss (n=122) –11·0 (–25·6 to 3·5)
Constipation (n=121) –2·2 (–14·0 to 9·6)
Diarrhoea (n=119) 2·3 (–6·6 to 11·2)
Financial difficulties (n=121) –0·8 (–11·8 to 10·1)
FA13 scores‡
Physical fatigue (n=112) 8·3 (–3·9 to 20·6)
Emotional fatigue (n=112) 8·5 (–3·4 to 20·4)
Cognitive fatigue (n=112) 3·9 (–4·6 to 12·4)
Interference with daily life (n=111) 5·5 (–8·3 to 19·4)
Social sequelae (n=111) 2·4 (–8·5 to 13·2)
*From a linear regression model, adjusting for baseline score, histological subtype, 
and time since baseline. Treatment effect is calculated as: (gemcitabine and 
docetaxel change from baseline) – (doxorubicin change from baseline). †Higher 
scores are associated with better quality of life; a positive number indicates better 
functioning and quality of life on gemcitabine and docetaxel than on doxorubicin. 
‡Lower scores are associated with better quality of life; a positive number indicates 
worse symptoms on gemcitabine and docetaxel than on doxorubicin. C30=EORTC 
core quality-of-life questionnaire. FA13=fatigue questionnaire. 
Table 4: Difference in quality-of-life outcomes at 12 weeks after 
randomisation 
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doxorubicin (61 [42%] of 145 prescriptions; appendix p 16), 
gemcitabine and docetaxel (19 [13%]), ifosfamide (17 [12%]), 
trabectedin (13 [9%]), pazopanib (nine [6%]), and 
gemcitabine (seven [5%]; appendix p 16). Information 
about the outcomes of these additional treatments (local 
therapies and chemotherapy) was not collected.
Discussion
In this randomised phase 3 trial of gemcitabine and 
docetaxel compared with doxorubicin as first-line therapy 
for locally advanced or metastatic soft-tissue sarcoma, we 
found no significant difference between the two treatment 
groups for the primary endpoint of the proportion of 
patients alive and progression free at 24 weeks. Similarly, 
we found no significant difference in overall survival 
between the two treatment groups. Soft-tissue sarcoma is 
recognised to be a very heterogeneous disease with a large 
number of histological subtypes, and indeed our trial 
included 22 different subtypes, with very small numbers of 
patients with many of these subtypes. This heterogeneity 
is an inevitable feature of most large soft-tissue sarcoma 
trials, and as such we believe that the GeDDiS trial 
population is representative of the general population with 
advanced soft-tissue sarcoma.
Gemcitabine and docetaxel has been used in locally 
advanced or metastatic soft-tissue sarcoma since 2002, and 
has been investigated in several small studies, which have 
shown activity of the combination therapy.6–9,11,12 
A randomised phase 2 study compared gemcitabine and 
docetaxel with gemcitabine alone in 122 patients with 
advanced soft-tissue sarcoma who had received between 
zero and three previous chemotherapy regimens, and 
reported superior median progression-free survival for 
gemcitabine and docetaxel compared with gemcitabine 
alone (6·2 months vs 3·0 months) and overall 
survival (17·9 months vs 11·5 months).13 A subsequent 
randomised phase 2 study compared gemcitabine and 
docetaxel versus gemcitabine alone as second-line 
treatment in 90 patients with leiomyosarcoma, reporting 
that both schedules were effective second-line therapies, 
with similar proportions of patients achieving a response.10 
Gemcitabine and docetaxel has therefore become an 
accepted treatment option in metastatic soft-tissue 
sarcoma after first-line therapy.24 Subsequent phase 1b/2 
studies have combined gemcitabine and docetaxel with 
bevacizumab showing feasibility and activity,25,26 and also 
with pazopanib,27 although that trial closed early because of 
slow accrual and substantial toxicity. A placebo-controlled 
phase 3 trial28 of gemcitabine and docetaxel in combination 
with bevacizumab in metastatic uterine leiomyosarcoma 
for first-line treatment did not show a benefit for 
progression-free survival or overall survival.
Since the first published study6 of gemcitabine and 
docetaxel, which was confined to patients with 
leiomyosarcoma, some clinicians have assumed that the 
combination is more active in leiomyosarcoma and uterine 
leiomyosarcoma than in other histological subtypes. 
Indeed, several studies8–11,28 have restricted the use of 
gemcitabine and docetaxel to leiomyosarcoma and uterine 
leiomyosarcoma. However, the results of the GeDDiS trial 
refute these claims of superior activity in particular 
histological subtypes of locally advanced or metastatic soft-
tissue sarcoma versus others, since our results show no 
evidence that treatment effect was influenced by 
histological subtype. We did planned subgroup analyses 
to investigate whether patients with either leiomyo-
sarcoma or uterine leiomyosarcoma responded better to 
gemcitabine and docetaxel than other soft-tissue sarcoma 
histological subtypes, but found no indication of a superior 
response to gemcitabine and docetaxel in either of these 
subgroups.
We chose 13 years as the minimum age for the trial, 
specifically to try to increase participation of the teenage 
and young adult population, because clinical trial 
recruitment of this age group is recognised to be poor.29 
However, only one patient younger than 18 years of age 
was recruited, which we believe reflects the differing 
approaches to treatment of advanced soft-tissue sarcoma 
by UK paediatric and adult oncologists—with paediatric 
oncologists using more intensive chemotherapy regimens 
than those used in this trial. Additionally, competing 
paediatric trials in this population were running in the UK 
at the time of recruitment to GeDDiS, such that we believe 
that younger patients were preferentially recruited to those 
paediatric trials.
Why did gemcitabine and docetaxel fail to show 
superiority to doxorubicin? This outcome might have been 
Overall
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Figure 4: Quality-of-life outcomes at 12 weeks post-randomisation 
The plotted points represent the mean treatment effect between the groups (a positive number for the treatment 
effect indicates a better quality of life on gemcitabine and docetaxel than doxorubicin). For symptom scales and 
FA13 scores, lower scores are associated with better quality of life. Consequently, values are the opposite between 
table 4 and figure 4); horizontal lines are 99% CIs. FA13=fatigue questionnaire. 
Articles
1408 www.thelancet.com/oncology   Vol 18   October 2017
partly due to the choice of lower dose and fewer cycles of 
treatment; the 2002 study by Hensley and colleagues6 
delivered more cycles (eight vs six), at higher doses 
(gemcitabine 900 mg/m² and docetaxel 100 mg/m² vs 
gemcitabine 675 mg/m² and docetaxel 75 mg/m²) than in 
GeDDiS. Our regimen was chosen on the basis of the 
randomised phase 2 study of Maki and colleagues,13 which 
had used the higher dose schedule, and had reported high 
frequency (46%) of dose reductions for gemcitabine and 
docetaxel, lower dose intensity than gemcitabine, and 
more than 40% of patients on gemcitabine and docetaxel 
stopping within 6 months of starting therapy, for non-
haematological toxicities such as fatigue and myalgias, 
despite dose reductions. The authors concluded that “this 
dose and schedule…are too high for long-term use”. 
Additionally, a previous phase 2 study11 that the GeDDiS 
chief investigator had led using this schedule had found 
that quite substantial toxicity was experienced in the UK 
population, such that eight (18%) of 45 patients stopped 
treatment early due to toxicity, and only ten (20%) patients 
received the full eight cycles. We therefore made a 
pragmatic decision to dose modify the schedule to make it 
more suitable for patients receiving palliative 
chemotherapy. The lower doses used are reflected by the 
absence of grade 3–4 thrombocytopenia recorded (no 
patients on gemcitabine and docetaxel experienced this 
toxicity) compared with a 40% frequency in the previous 
randomised phase 2 study.13 It might be suggested that the 
gemcitabine and docetaxel doses we selected were too low. 
However, despite modifying the gemcitabine and docetaxel 
schedule for the GeDDiS trial, our results were similar for 
gemcitabine and docetaxel to those of Maki and colleagues’ 
study,13 with median progression-free survival of 
5·5 months versus 6·2 months, and median overall 
survival of 15·5 months versus 17·9 months, respectively.
An additional factor in the lack of superiority of 
gemcitabine and docetaxel over doxorubicin at least for 
overall survival might be the lower overall exposure of 
patients to gemcitabine and docetaxel, as first-line and 
second-line treatments combined. Of 96 patients in the 
gemcitabine and docetaxel group receiving a subsequent 
treatment, 60 received doxorubicin, whereas of 
100 patients in the doxorubicin group receiving a 
subsequent treatment, only 18 received gemcitabine and 
docetaxel. This difference is because for many UK 
hospitals at the time of the GeDDiS trial, the combination 
of gemcitabine and docetaxel was not funded and thus 
unavailable to clinicians.
Despite the use of a modified gemcitabine and docetaxel 
schedule in our study, treatment adherence to gemcitabine 
and docetaxel was inferior to that for doxorubicin. Patients 
in the gemcitabine and docetaxel group experienced more 
dose delays and lower dose intensity than those in the 
doxorubicin group, with fewer patients in the gemcitabine 
and docetaxel group receiving all six cycles of 
chemotherapy and more patients stopping treatment 
early due to toxicity. These findings might have a number 
of explanations. A proportion of patients (4% to 10%) at 
each cycle did not receive day 8 docetaxel, thus affecting 
dose intensity. Docetaxel was omitted at these points 
according to protocol criteria for low neutrophils or 
platelets, or toxicity leading to a clinical decision to omit 
docetaxel (notably, the most common non-haematological 
grade 3–4 toxicity in the gemcitabine and docetaxel group 
was fatigue). The excess of patients stopping gemcitabine 
and docetaxel early might also have reflected a bias in 
clinicians to stop treatment earlier in the experimental 
group, in the knowledge that patients could go on to 
receive standard doxorubicin-based treatment. It could be 
argued that the gemcitabine and docetaxel doses that 
were delayed or missed represent undertreatment in this 
group, which could explain the separation of the 
progression-free survival curves in figure 2.
Although no significant difference was seen in any of the 
individual quality-of-life parameters between the treatment 
groups, the global health status was numerically lower for 
gemcitabine and docetaxel than in the doxorubicin group. 
Potential contributing factors are that gemcitabine and 
docetaxel requires an additional visit to hospital in each 
3-week cycle, and gemcitabine and docetaxel takes longer 
to deliver than doxorubicin, prolonging each hospital visit 
and resulting in an added burden on patients with 
incurable disease receiving palliative chemotherapy. The 
implication of these results is that gemcitabine and 
docetaxel was more difficult to deliver (lower dose intensity, 
more treatment delays, and more patients stopping early 
due to toxicity), and was associated with a worse global 
health status than doxorubicin. Thus, there does seem to 
be a disadvantage to patients in receiving gemcitabine and 
docetaxel as first-line treatment. Furthermore, there are 
economic, as well as personal, disadvantages to 
gemcitabine and docetaxel because it is a more expensive 
treatment regimen than doxorubicin because of higher 
drug costs, more frequent and longer hospital visits are 
needed for treatment, and increased requirements for 
supportive medications (data not shown).
Importantly, the results of the current study are 
consistent with two other first-line studies in locally 
advanced or metastatic soft-tissue sarcoma that included 
doxorubicin as the control group, with the median 
progression-free survival of 23·3 weeks in the 
doxorubicin group in the current study similar to the 
22·5 weeks4 and 26 weeks5 reported in the other studies. 
This is also true of median overall survival, which was 
76·3 weeks in the doxorubicin group in the current study, 
compared with 73·2 weeks4 and 82·3 weeks5 with 
doxorubicin in the other studies. Interestingly, all 
three studies showed an improvement in progression-
free survival and overall survival compared with the 
preceding published trial of Judson and colleagues2 
(progression-free survival of 19·9 weeks and overall 
survival of 55·4 weeks), which had recruited patients 
several years earlier, suggesting that outcomes have 
improved for patients with locally advanced or metastatic 
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soft-tissue sarcoma in recent years. The explanation for 
this is likely to be multifactorial. Clinicians might be 
better at selecting patients most likely to benefit from 
palliative chemotherapy for advanced soft-tissue sarcoma, 
and are treating patients more aggressively in terms of 
minimising dose reductions and treatment delays, with 
greater use of supportive medications such as growth 
factors. A further factor might be increasing use of local 
therapies such as radiotherapy and surgery for patients 
with metastatic disease, which has been associated with 
longer overall survival than for patients not receiving 
such therapies.30 Indeed, 57 patients on the GeDDiS trial 
went on to receive surgery or radiotherapy after 
completing study treatment.
The pharmacogenomics data obtained in the current 
study suggest that SNPs in the organic cation transporter 
SLC22A16 are associated with reduced efficacy and 
decreased toxicity following doxorubicin treatment. 
These findings are in keeping with previously published 
data from a breast cancer patient cohort and are 
consistent with a loss of function in the transporter that 
results in reduced intracellular influx of doxorubicin.20 
Validation of these effects in an independent cohort of 
sarcoma patients would be valuable to ascertain the 
potential for this SNP to influence clinical decision-
making. Two other SNPs, SLC29A1 rs9394992 and 
PRDX4 rs518329, were also associated with outcomes in 
the doxorubicin group; however, these genes are not 
known to be involved in the pharmacology of doxorubicin, 
so further investigation is required to understand these 
effects. There were indications that three SNPs predicted 
to affect gemcitabine pharmacokinetics were associated 
with an effect on overall survival, most notably the CDA 
rs2072671 SNP, which was associated with reduced 
overall survival in the gemcitabine and docetaxel group, 
with worse survival in patients homozygous (rather than 
heterozygous) for the minor allele (this is referred to as a 
gene-dose effect). However, the same SNP was not 
associated with a difference in progression-free survival, 
and insufficient evidence is currently available to 
advocate routine testing of these SNPs to influence 
clinical decision-making.
Limitations of the current study include the fact that we 
used a gemcitabine and docetaxel schedule that used fewer 
cycles and lower doses than in the originally published 
schedule,6 which is widely used in other countries. 
Although we had a clear rationale for this decision, 
nevertheless we acknowledge that some might conclude 
that this limits the applicability of the trial results to the 
wider population of patients with advanced soft-tissue 
sarcoma beyond our trial. Additionally, more patients 
stopped treatment early on gemcitabine and docetaxel 
than doxorubicin, which might have reflected the fact that 
clinicians knew that patients could go on to receive 
doxorubicin, whereas the reverse was not true due to the 
limited availability of gemcitabine and docetaxel in the UK 
at that time outside of clinical trials.
How should these results inform our discussions with 
patients with advanced soft-tissue sarcoma? The data do 
not support superiority for gemcitabine and docetaxel over 
doxorubicin on survival outcomes. Subgroup analyses 
have not identified any subgroup for which gemcitabine 
and docetaxel was superior, and in particular we did not 
observe superiority for either leiomyosarcoma or uterine 
leiomyosarcoma. Although the similar progression-free 
survival and overall survival of gemcitabine and docetaxel 
and doxorubicin might support a conclusion that either 
schedule can be used according to patient or clinician 
preference, our results indicate the need for caution with 
such an approach, in that gemcitabine and docetaxel is 
more difficult to deliver than doxorubicin, and patients 
find it more toxic than doxorubicin, with some effects on 
quality of life. Furthermore, economic factors should be 
considered with the higher cost of the gemcitabine and 
docetaxel schedule. Thus, the overall clinical conclusion 
should be that doxorubicin remains standard of care as 
first-line treatment for locally advanced or metastatic soft-
tissue sarcoma, and that gemcitabine and docetaxel is not 
recommended as routine first-line treatment. There might 
of course be occasions when different choices are made 
depending on patient factors and preferences, such as 
using combination doxorubicin and ifosfamide for selected 
patients who need to optimise chances of tumour 
shrinkage, or using gemcitabine and docetaxel in patients 
with cardiac dysfunction that contraindicates use of 
doxorubicin. However, for most patients, these results will 
hopefully provide evidence for clinicians to consider with 
their patients when selecting first-line treatment for 
advanced soft-tissue sarcoma. The study also highlights 
the importance of doing randomised trials in rare cancers 
to rigorously compare new treatments with established 
standard treatments, rather than extrapolating promising 
results from smaller non-comparative trials.
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